20978 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Interferons [IFN]
Estrogen receptor ligand treatment for neurodegenerative diseases
#302IMMUNOMODULATORY MATERIALS FOR IMPLANTABLE MEDICAL DEVICES
#303Combination therapy for inducing immune response to disease
#304Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
#305ANTIBODY COMPOSITION FOR PREVENTION OR TREATMENT OF MUTANT HEPATITIS B VIRUS INFECTION
#306Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof
#307T-cell redirecting bispecific antibodies for treatment of disease
#308SMC combination therapy for the treatment of cancer
#309Methods for diagnosing and treating Alzheimer's disease
#310Stabilization of Aqueous Compositions of Proteins With Displacement Buffers
#311Macrocyclic inhibitors of flaviviridae viruses
#312Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#313Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
#314Combination therapy for treatment of HBV infections
#315TWO-PIECE, INTERNAL-CHANNEL OSMOTIC DELIVERY SYSTEM FLOW MODULATOR
#316Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
#317Use of vitelline protein B as a microencapsulating additive
#318Transdermal delivery of high viscosity bioactive agents
#319Inhibitors and methods of inhibiting bacterial and viral pathogens
#320MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS
#321ANTIVIRAL COMPOUNDS
#322Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods
#323Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair
#324SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES
#325Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent
#326Treatment of thrombocytopenia using orally administered interferon
#327Treatment of hepatitis delta virus infection
#328Methods of treating coronavirus infection
#329T-cell redirecting bispecific antibodies for treatment of disease
#330Cyclopamine analogs
#331Combination therapy for inducing immune response to disease
#332Azepane derivatives and methods of treating hepatitis B infections
#333PEROXIDE REMOVAL FROM DRUG DELIVERY VEHICLE
#334Inhibitors of hepatitis C virus
#335COMPOSITIONS OF POLYUNSATURATED FATTY ACIDS AND METHODS OF USE THEREOF
#336Process for preparing antiviral compounds
#337METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#338Small molecule enhancer for dendritic cell cancer vaccines
#339Increasing cancer patient survival time by administration of dithio-containing compounds
#340Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
#341DIAGNOSTIC METHODS AND KITS FOR DETERMINING A PERSONALIZED TREATMENT REGIMEN FOR A SUBJECT SUFFERING FROM A PATHOLOGIC DISORDER
#342Disease therapy by inducing immune response to Trop-2 expressing cells
#343MICRONEEDLE ARRAYS FOR ACTIVE AGENT DELIVERY
#344S1P modulating agents
#345Crk—a novel target for cancer therapy
#346Use of Let-7g to down regulate NS5B gene, core protein and viral load of hepatitis C virus
#347POLYCYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
#348Controlled release pharmaceutical formulations of nitazoxanide
#349Method for increasing interferon activity in an individual
#3504′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
#351Inhibitors of endoglin activity for the treatment of fibrosis
#352Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#353T-cell redirecting bispecific antibodies for treatment of disease
#3542′-branched nucleosides and flaviviridae mutation
#355Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
#356Combinations comprising biphenyl derivatives for use in the treatment of HCV
#357Methods of use of cyclopamine analogs
#358Chemical compounds
#359THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
#360Pharmaceutical composition for viral immunotherapy and uses thereof
#361Cyclosporin analogues for preventing or treating hepatitis C infection
#362Cyclosporin analogues for preventing or treating hepatitis C infection
#363Topical therapeutic formulations
#364Interferon lambda-antibody complexes
#365Placental stem cell populations
#366Antiviral compounds and methods of use thereof
#367Antiviral compounds
#368Immunity induction agent
#369Treatment of cancer with immune stimulators
#370METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN
#371DERIVATISATION OF BIOLOGICAL MOLECULES
#372Allogeneic T-cell compositions for induction of IL-12
#373Inhibitors and methods of inhibiting bacterial and viral pathogens
#374Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
#375Cyclosporin analogues for preventing or treating hepatitis C infection
#3762′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
#377Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
#378Bruton's tyrosine kinase inhibitor combinations and uses thereof
#379Method for producing soluble recombinant interferon protein without denaturing
#380Immunity inducing agent
#381A METHOD FOR TREATING TUMOR BY USING RECOMBINANT INTERFERON WITH CHANGED SPATIAL CONFIGURATION
#382HIGHLY CONCENTRATED DRUG PARTICLES, FORMULATIONS, SUSPENSIONS AND USES THEREOF
#383Activation of innate immunity by miRNA for cancer and infection treatment
#384Modulators of toll-like receptors
#385ANTIVIRAL COMPOUNDS
#386Azepane derivatives and methods of treating hepatitis B infections
#387Antiviral compounds
#388Polymeric system for release of an active agent
#389Anti-histone therapy for vascular necrosis in severe glomerulonephritis
#390CONJUGATES AND SMALL MOLECULES WHICH INTERACT WITH THE CD16A RECEPTOR
#391Antiviral compounds
#392Methods and compositions for treatment of demyelinating diseases
#393METHODS AND COMPOSITIONS FOR TREATMENT OF BONE, SKIN, SUBCUTANEOUS, MUCOSAL AND/OR SUBMUCOSAL CANCER BY PERCUTANEOUS AND/OR TRANSMUCOSAL ADMINISTRATION OF INTERFERON
#394Macrocyclic inhibitors of flaviviridae viruses
#395Substituted quinoline compounds and methods of use
#396Process for preparing products comprising stabilised actives and compositions comprising same
#397Systems and methods for targeted imaging and ablation of cardiac cells
#398METHOD FOR INTRODUCING BIOLOGICALLY ACTIVE SUBSTANCES INTO THE BRAIN
#399HBV RNASE H PURIFICATION AND ENZYME INHIBITORS
#400Ammonium derivatives for the treatment of hepatitis C
#401Therapeutic methods
#402Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
#403Azepane derivatives and methods of treating hepatitis B infections
#404ANTIVIRAL COMPOUNDS
#405Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
#406COMPOSITIONS AND METHODS FOR INCREASING PROTEIN HALF-LIFE
#407Hepatitis C virus inhibitors
#408Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
#409Solvent/polymer solutions as suspension vehicles
#410Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer
#411Macrocyclic inhibitors of flaviviridae viruses
#412TREATMENTS OF HEPATITIS C VIRUS INFECTION
#413SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF CATIONIC PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
#414Hepatitis B antiviral agents
#415Hepatitis C virus inhibitors
#416Azepane derivatives and methods of treating hepatitis B infections
#417DRUG-ELUTING MEDICAL DEVICES
#418Process for preparing antiviral compounds
#419Method for treating virus infection using derivative of aniline
#420USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE
#421Method of diagnosis and treatment
#422Antibody composition for prevention or treatment of mutant hepatitis B virus infection
#423Inhibitors of HCV NS5A
#424Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#425TLR5 ligands, therapeutic methods, and compositions related thereto
#426Hepatitis B antiviral agents
#427Methods and compositions for oral administration of protein and peptide therapeutic agents
#428Methods for modulating immune responses
#429Substituted nucleotide analogs
#430Antiviral compounds
#431Cancer stem cell targeted cancer vaccines
#432Treatment of thrombocytopenia using orally administered interferon
#433Azepane derivatives and methods of treating hepatitis B infections
#434Disease therapy by inducing immune response to Trop-2 expressing cells
#435Orally bioavailable lipid-based constructs
#436Hepatitis C virus inhibitors
#437Substrates and inhibitors of prolyl oligopeptidase and methods of use
#438Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
#439Cytokines and neuroantigens for treatment of immune disorders
#440Stable liquid interferon beta formulations
#441Agent for the treatment of viral hepatitis C
#442Cyclosporin analogues for preventing or treating hepatitis C infection
#443TREATMENT OF FIBROSIS
#444Anti-TNF antibody formulations
#445Treatment for melanoma
#446Hepatitis C Virus Inhibitors
#447Method of treating food allergies by administering a nanoparticle comprising heparin and chitosan encapsulating IL-12
#448Method for reducing injury and stabilizing muscle using orally administered interferon
#449Placental stem cell populations
#450HCV IMMUNOTHERAPY
#451Cyclopamine analogs
#452Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
#453Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
#454Vaccine immunotherapy for treating cervical cancer in immune suppressed patients
#455Vaccine immunotherapy for treating lymphoma in immune suppressed patients
#456Benzimidazole derivatives
#457Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
#458Methods comprising dosing combinations for reducing undesired humoral immune responses
#459Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
#460Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
#461Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
#462Use of metallocene compounds for cancer treatment
#463INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
#464Modulators of toll-like receptors
#465Antiviral compounds
#466Hepatitis C virus inhibitors
#467BIOMARKERS FOR HCV INFECTED PATIENTS
#468Combination therapy with interferon and andrographolides for Multiple Sclerosis
#469HCV NS3 protease inhibitors
#4702′,4′-fluoro nucleosides for the treatment of HCV
#471PEPTIDOMIMETIC PROTEASE INHIBITORS
#472Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
#473Small molecule enhancer for dendritic cell cancer vaccines
#474SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS
#475Amino acid substituted molecules
#476Anti-HCV agent
#477Inhibition of innate immune response
#478Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#479Device, system and methods for the oral delivery of therapeutic compounds
#4805, 6-Duridine nucleoside/tide derivatives
#481Therapeutic methods
#482MACROCYCLES
#483Hepatitis C Virus Inhibitors
#484STABILIZED LIQUID FORMULATION
#485Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
#486Hepatitis B antiviral agents
#4874′-fluoro nucleosides for the treatment of HCV
#488Hepatitis B antiviral agents
#489Antiviral compounds
#490[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
#491Method for attenuating immune response using mesenchymal stem cells and cytokines
#492Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
#493Type I interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
#494Adjuvant incorporation in immunoanotherapeutics
#495ANTIVIRAL ACTIVITY OF TYROSINE KINASE INHIBITORS AGAINST HEPATITUS C VIRUS
#496IMMUNITY INDUCING AGENT
#497Viral hepatitis treatment
#498Antiviral compounds
#499Methods of use of cyclopamine analogs
#500Combination therapy for inducing immune response to disease
#501Tetrazolones as inhibitors of fatty acid synthase
#502Pyrimidinone compounds and methods for treating influenza
#503Immunomodulatory materials for implantable medical devices
#504Controlled release pharmaceutical formulations of nitazoxanide
#5052'-Branched Nucleosides for Treatment of Viral Infections
#506VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#507Treating hepatitis C virus infection
#508ANALYSIS OF HCV GENOTYPES
#509T-cell redirecting bispecific antibodies for treatment of disease
#510Methods and pharmaceutical compositions for inhibiting influenza viruses replication
#511Macrocyclic inhibitors of flaviviridae viruses
#512Inhibitors of hepatitis C virus
#513Hepatitis C virus inhibitors
#514Treatment with factor ix-albumin fusion protein
#515ANTIVIRAL COMPOUNDS
#516Antibacterial agent for treating infectious diseases of bacterial origin
#517Treatment with factor VII-albumin fusion protein
#518Treatment of inflammatory diseases using placental stem cells
#519Macrocyclic inhibitors of flaviviridae viruses
#520Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
#521CULTURING CIRCULAR ssDNA VIRUSES FOR THE PRODUCTION OF VACCINES
#522METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS
#523METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS
#524Methods and compositions for treating flaviviruses and pestiviruses
#525Oligonucleotide chelate complex—polypeptide compositions and methods
#526ANTIVIRAL COMPOUNDS
#527Antiviral compounds
#528Methods for modulating immune responses
#529Stable liquid interferon beta formulations
#530IDENTIFICATION OF NATURAL PLANT EXTRACTS HARBORING ANTI-HEPATITIS C VIRUS NS5B POLYMERASE ACTIVITY
#531USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
#532Linked dibenzimidazole antivirals
#533Methods for reducing the risk of spontaneous abortion in a human female comprising administering an effective amount of G-CSF
#534Therapies for Treating Hepatitis C Virus Infection
#535Albumin Fusion Proteins
#536Hyaluronic acid-protein conjugates and method for preparing same
#537Methods for Modulating Inflammatory Responses
#538Silibinin component for the treatment of hepatitis
#539PEG-interferon λ1 conjugates and methods of treating viral infections
#540Process for preparing antiviral compounds
#541Compositions and methods for inhibiting entry of a hepatic virus
#542Anti-virus therapy for respiratory diseases
#543COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS
#544HIGH POTENCY FORMULATIONS OF VX-950
#545Methods of increasing efficiency of vector penetration of target tissue
#546Methods and compositions concerning poxviruses and cancer
#547Hepatitis C virus inhibitors
#548Cyclosporin analogues for preventing or treating hepatitis C infection
#549COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
#550MIA-2 PROTEIN
#551Antiviral compounds
#552Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#553Cancer therapy based on tumor associated antigens derived from cyclin D1
#554Pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder
#555METHODS FOR TREATING VIRAL CONDITIONS
#556Heterocyclic flaviviridae virus inhibitors
#5573-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
#558Device, system and methods for the oral delivery of therapeutic compounds
#559Substituted nucleotide analogs
#560Protein formulations and methods of making same
#561INFLUENZA VIRUS POPULATIONS, METHODS OF USE AND METHODS OF MAKING THEREOF
#562Methods and compositions for treating hepatitis C virus
#563Hepatitis C virus inhibitors
#564Interferon lambada-antibody complexes
#565Adjuvant incorporation in immunonanotherapeutics
#566Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
#567COMBINATION OF ANTI-ENVELOPE ANTIBODIES AND ANTI-RECEPTOR ANTIBODIES FOR THE TREATMENT AND PREVENTION OF HCV INFECTION
#568INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION
#569Tripeptides Incorporating Deuterium as Inhibitors of Hepatitis C Virus
#570Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
#571Microvesicles derived from cell protoplast and use thereof
#572Hepatitis C virus inhibitors
#573Methods of use of cyclopamine analogs
#574AGENT FOR TREATING HCV INFECTION
#575Lysine demethylase inhibitors for diseases and disorders associated with
#576Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
#5772′-chloroacetylenyl substituted nucleoside derivatives
#578METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS
#579Modulators of toll-like receptors
#580Antiviral compounds and methods of use thereof
#5815,5-fused arylene or heteroarylene hepatitis C virus inhibitors
#582Interferon analogs
#583COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS
#584INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS
#585COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES
#586ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY
#587ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES
#588ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES
#589INNOCULATION OF RECOMBINANT VIRAL VECTORS FOR RAPID PRE-EXPOSURE PREVENTION AND POST-EXPOSURE PROTECTION AGAINST ALPHAVIRUS-INDUCED ENCEPHALITIDES
#590INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES
#591INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS
#592DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS
#593TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE
#594THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE
#595Methods of manufacturing viscous liquid pharmaceutical formulations
#596Solvent/polymer solutions as suspension vehicles
#597Solvent/polymer solutions as suspension vehicles
#598Placental stem cell populations
#599ANTI-INFLAMMATORY COMPOSITIONS FOR TREATING BRAIN INFLAMMATION
#600Methods for treating nicotine addiction and reducing food consumption